Stocktoria
Fresenius SE & Co. KGaA FRE.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Fresenius SE & Co. KGaA financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $22.9B | $22.0B | $21.1B | $21.5B |
| Gross profit | $5.7B | $5.6B | $5.0B | $5.4B |
| R&D expense | $633.0M | $641.0M | $661.0M | $639.0M |
| SG&A expense | $2.9B | $2.9B | $3.0B | $3.1B |
| Operating income | $2.2B | $2.1B | $1.2B | $1.8B |
| Interest expense | $445.0M | $552.0M | $519.0M | $345.0M |
| Income tax | $582.0M | $530.0M | $485.0M | $375.0M |
| Net income | $1.3B | $471.0M | -$594.0M | $1.4B |
| EPS (diluted) | $2.24 | $0.84 | $-1.05 | $2.44 |
| Operating cash flow | $2.6B | $2.4B | $4.5B | $4.2B |
| Free cash flow | $1.1B | $1.4B | $3.2B | $3.0B |
| Cash & equivalents | $1.3B | $2.0B | $2.3B | $2.6B |
| Inventory | $2.6B | $2.6B | $2.5B | $4.8B |
| Total assets | $41.4B | $43.5B | $45.3B | $76.4B |
| Total liabilities | $21.6B | $23.3B | $25.6B | $44.2B |
| Shareholders' equity | $19.1B | $19.5B | $19.0B | $20.4B |
Growth · year-over-year · Revenue CAGR 2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +4.2% | +4.2% | -2.2% | — |
| Net income growth | +168.4% | — | -143.3% | — |
| EPS growth | +166.7% | — | -143.0% | — |
| Free cash flow growth | -22.4% | -56.2% | +5.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · DE · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.